Centre for Integrated research into Musculoskeletal Ageing (CIMA) Renewal
Lead Research Organisation:
University of Liverpool
Department Name: Institute of Ageing and Chronic Disease
Abstract
Overview
The MRC-Arthritis Research UK Centre for Integrated Research into Musculoskeletal Ageing (CIMA) is a unique team. CIMA brings in a mix of skills from three major U.K. Universities: Liverpool, Newcastle and Sheffield. It helps doctors and lab scientists to work together to grasp:
1) How our muscles, bones and joints change as we age.
2) How this makes some people prone to problems with these tissues such as arthritis and osteoporosis.
3) What each person can do to reduce the risk of developing these problems.
Progress So Far
CIMA was first funded for 5 years in 2012. CIMA has made great progress in figuring out some key processes in muscles, bones and joints as we age. As well as working out what might reduce the risk of developing these problems, we have also done trials of some likely nutritional agents. These might reduce age-related decline in muscles, bones and joints. We have obtained some early evidence that raising vitamin D may help reduce age-related decline, but putting up nitrate intake may not help. A big limit to expanding research in this important area has also been a lack of well-trained researchers and doctors. So the Centre has also developed and run good training courses to meet this need.
Future: Targets, Treatments & Training
This bid is for 5 more years of funding from the Medical Research Council (MRC) and Arthritis Research UK to help build on this work. Our first phase of funding has let the CIMA members spot certain changes to cells- called epigenetic changes. These seem vital in influencing whether muscles, bones and joint tissues decline quickly or slowly as we age. We plan to do a linked research programme across Liverpool, Newcastle and Sheffield. This will seek to work out the importance of these changes and whether we can modify the changes to reduce the risk of getting muscle, bone and joint problems. We will also work together to look more closely at whether nutrition and exercise can prevent or reduce the risk of these problems. We also plan to expand our training programme so more basic scientists and doctors can do excellent research into these problems. Key results will be shared in papers and meetings. More funding bids will be made to do this work.
Patient View
People with arthritis have helped to shape this bid. By joining a series of "Arthritis Matters" Public Engagement events, for example. These have helped the public grasp CIMA's research and shape future priorities. Above all this includes a grasp of new arthritis treatments and how study findings can benefit patients. We also asked a group of 15 patients to advise on the final lay summary. We think talking to patients often about research and listening to their views makes for better research.
Better Engagement
Going forward, patients and the public will continue to be actively involved by providing insight and valued feedback in many ways. Face to face meetings will remain a key part. And more events will be used, including local, national and global schemes. There will be new work with schools, to share CIMA's work, inspire new ideas and nurture talent. The VOICE North digital platform will support this across the Centre and more widely. The CIMA website will also be kept up to date and advances shared on Twitter. We know most older people don't use these yet, but that could change quickly as access gets easier and cheaper. We expect young people to help make solutions for this. We will also increase our work with drug companies, local authorities and the NHS. This will allow us to develop ways to make sure our findings are quickly put into practice to benefit older people. Arthritis is also one of a key number of conditions included in the NIHR James Lind Alliance Priority Setting Partnership on Ageing and Multiple conditions, led by Newcastle University. This will provide more chances for patients who have arthritis to be involved and link to CIMA.
The MRC-Arthritis Research UK Centre for Integrated Research into Musculoskeletal Ageing (CIMA) is a unique team. CIMA brings in a mix of skills from three major U.K. Universities: Liverpool, Newcastle and Sheffield. It helps doctors and lab scientists to work together to grasp:
1) How our muscles, bones and joints change as we age.
2) How this makes some people prone to problems with these tissues such as arthritis and osteoporosis.
3) What each person can do to reduce the risk of developing these problems.
Progress So Far
CIMA was first funded for 5 years in 2012. CIMA has made great progress in figuring out some key processes in muscles, bones and joints as we age. As well as working out what might reduce the risk of developing these problems, we have also done trials of some likely nutritional agents. These might reduce age-related decline in muscles, bones and joints. We have obtained some early evidence that raising vitamin D may help reduce age-related decline, but putting up nitrate intake may not help. A big limit to expanding research in this important area has also been a lack of well-trained researchers and doctors. So the Centre has also developed and run good training courses to meet this need.
Future: Targets, Treatments & Training
This bid is for 5 more years of funding from the Medical Research Council (MRC) and Arthritis Research UK to help build on this work. Our first phase of funding has let the CIMA members spot certain changes to cells- called epigenetic changes. These seem vital in influencing whether muscles, bones and joint tissues decline quickly or slowly as we age. We plan to do a linked research programme across Liverpool, Newcastle and Sheffield. This will seek to work out the importance of these changes and whether we can modify the changes to reduce the risk of getting muscle, bone and joint problems. We will also work together to look more closely at whether nutrition and exercise can prevent or reduce the risk of these problems. We also plan to expand our training programme so more basic scientists and doctors can do excellent research into these problems. Key results will be shared in papers and meetings. More funding bids will be made to do this work.
Patient View
People with arthritis have helped to shape this bid. By joining a series of "Arthritis Matters" Public Engagement events, for example. These have helped the public grasp CIMA's research and shape future priorities. Above all this includes a grasp of new arthritis treatments and how study findings can benefit patients. We also asked a group of 15 patients to advise on the final lay summary. We think talking to patients often about research and listening to their views makes for better research.
Better Engagement
Going forward, patients and the public will continue to be actively involved by providing insight and valued feedback in many ways. Face to face meetings will remain a key part. And more events will be used, including local, national and global schemes. There will be new work with schools, to share CIMA's work, inspire new ideas and nurture talent. The VOICE North digital platform will support this across the Centre and more widely. The CIMA website will also be kept up to date and advances shared on Twitter. We know most older people don't use these yet, but that could change quickly as access gets easier and cheaper. We expect young people to help make solutions for this. We will also increase our work with drug companies, local authorities and the NHS. This will allow us to develop ways to make sure our findings are quickly put into practice to benefit older people. Arthritis is also one of a key number of conditions included in the NIHR James Lind Alliance Priority Setting Partnership on Ageing and Multiple conditions, led by Newcastle University. This will provide more chances for patients who have arthritis to be involved and link to CIMA.
Technical Summary
The MRC-Arthritis Research UK Centre for Integrated research into Musculoskeletal Ageing (CIMA) brings together scientific and clinical expertise in different disciplines from the universities of Liverpool, Newcastle and Sheffield. Formed in 2012, CIMA has developed an integrated approach to study the effects of ageing on the musculoskeletal system, which has been demonstrably successful. CIMA has focussed activities in areas of critical mass where collaborations have provided enhanced value. These include the role of epigenetic changes in cells and tissues affected by musculoskeletal ageing, development of an assessment protocol for monitoring age-related decline in the musculoskeletal system (the CIMA Toolkit), and proof of principle pre-clinical and human studies to identify interventions that reduce the deleterious effects of ageing on the musculoskeletal system. CIMA has developed an innovative graduate training programme and undertaken well-received public engagement activities. The revised CIMA strategy will be increasingly translational, but informed by basic research. Specifically, we will; determine how epigenetic changes in the ageing musculoskeletal system influence the risk of musculoskeletal disorders, the effect of modification of epigenetic changes on musculoskeletal function, and the effect of lifestyle changes on epigenetic marks and molecules; design and implement interventions based on physical activity, nutrition, anti-inflammatory or age-retarding agents on decline of the ageing musculoskeletal system; extend the CIMA training programme to increase MRes, PhD and clinical training, and; develop engagement and impact activities to increase involvement of patients and the older population, and work with industry and other partners to maximise translation of our research discoveries. Finally, it will provide a resilience that will ensure musculoskeletal ageing moves to the centre of medical research activities within and beyond the UK.
Planned Impact
CIMA renewal will contribute to all key impacts, including advancement of scientific knowledge, health and wellbeing, economic competitiveness, policy development and the provision of skilled people to the workforce. Our activities will supplement and complement existing programmes, harnessing the best practice at each of the centres to deliver excellence at all. In every area, the process will be a dialogue or platform of co-discovery, where both sides benefit from improved knowledge and understanding.
Benefits are targeted to the aging population and those who have conditions that are associated with accelerated ageing, for example those with systemic and local joint inflammation.
Potential impacts to the ageing population from advances in scientific knowledge include:
- direct benefits including learning and empowerment from contributing to the design and delivery of studies
- Improved ability to monitor age-related decline of the entire musculoskeletal system and the effects of potential interventions to reduce this through use of the CIMA Toolkit
- benefits from involvement in effective shared decision making using tools like FRAX for assessing fracture risk.
- wider understanding of musculoskeletal ageing from PPI and patient engagement, VOICENorth (Quote: 'We are volunteering the accumulated knowledge we have gathered over our entire life'.)
- better information about healthy ageing and how to achieve it from better trained experts and improved personal engagement from platforms including VOICENorth online and the MOOC.- enhanced understanding of mechanisms and targets, feeding directly into accelerated novel drug identification and development
- refining outcomes and delivering interventions that improve care and both scientific and clinical practice
Impacts for health and wellbeing include:
- improved pain, function and quality of life from participation in clinical trials and accruing to the wider population once interventions are proven effective
- high standard of care related to being involved in a clinical trial
- avoidance of harm from better targeting of therapy and toxicity identification of widely used drugs, such as paracetamol
- improved treatment options and prognostication
Impacts on economic competitiveness include:
- investment in research, delivering economic benefits for the centre and wider economy by a) health gains net of the cost of delivery, b) GDP gains from the activity and further stimulated activity
- these will come from new biomarkers, assessment tools, nutritional supplements and drugs, training and engagement activity
Impacts on policy development will include:
- benefits of more effective care, driven by NICE and other guidelines
- briefing MPs; advising expert panels, select committees, the Foresight programme (such as 'Future of an Ageing Population', 2016); WHO
- collaboration and advisory work for industry, including the CIMA Industrial Strategy Board
Impacts on provision of skilled workforce will include:
- better education and proactive identification of talented scientists from early identification and support for innovation from school sixth form onwards
- enhanced awareness of musculoskeletal ageing in trainee scientists and clinicians arising from exposure to the CIMA MOOC
- support for MRes and PhD students, postdoctoral and tenured scientists, who will contribute to training the next generation, specifically training to increase understanding of PPI and engagement.
- closer industry links leading to both funding of education and scientific posts by industry and flow of highly skilled workforce between academia and industry
Benefits are targeted to the aging population and those who have conditions that are associated with accelerated ageing, for example those with systemic and local joint inflammation.
Potential impacts to the ageing population from advances in scientific knowledge include:
- direct benefits including learning and empowerment from contributing to the design and delivery of studies
- Improved ability to monitor age-related decline of the entire musculoskeletal system and the effects of potential interventions to reduce this through use of the CIMA Toolkit
- benefits from involvement in effective shared decision making using tools like FRAX for assessing fracture risk.
- wider understanding of musculoskeletal ageing from PPI and patient engagement, VOICENorth (Quote: 'We are volunteering the accumulated knowledge we have gathered over our entire life'.)
- better information about healthy ageing and how to achieve it from better trained experts and improved personal engagement from platforms including VOICENorth online and the MOOC.- enhanced understanding of mechanisms and targets, feeding directly into accelerated novel drug identification and development
- refining outcomes and delivering interventions that improve care and both scientific and clinical practice
Impacts for health and wellbeing include:
- improved pain, function and quality of life from participation in clinical trials and accruing to the wider population once interventions are proven effective
- high standard of care related to being involved in a clinical trial
- avoidance of harm from better targeting of therapy and toxicity identification of widely used drugs, such as paracetamol
- improved treatment options and prognostication
Impacts on economic competitiveness include:
- investment in research, delivering economic benefits for the centre and wider economy by a) health gains net of the cost of delivery, b) GDP gains from the activity and further stimulated activity
- these will come from new biomarkers, assessment tools, nutritional supplements and drugs, training and engagement activity
Impacts on policy development will include:
- benefits of more effective care, driven by NICE and other guidelines
- briefing MPs; advising expert panels, select committees, the Foresight programme (such as 'Future of an Ageing Population', 2016); WHO
- collaboration and advisory work for industry, including the CIMA Industrial Strategy Board
Impacts on provision of skilled workforce will include:
- better education and proactive identification of talented scientists from early identification and support for innovation from school sixth form onwards
- enhanced awareness of musculoskeletal ageing in trainee scientists and clinicians arising from exposure to the CIMA MOOC
- support for MRes and PhD students, postdoctoral and tenured scientists, who will contribute to training the next generation, specifically training to increase understanding of PPI and engagement.
- closer industry links leading to both funding of education and scientific posts by industry and flow of highly skilled workforce between academia and industry
Publications

Clark B
(2019)
Consumers' perception of vitamin D and fortified foods
in British Food Journal

Clarke K
(2017)
The Role of Eif6 in Skeletal Muscle Homeostasis Revealed by Endurance Training Co-expression Networks.
in Cell reports

Clegg ME
(2018)
Optimizing nutrition in older people.
in Maturitas


Condurache CI
(2020)
Screening for high hip fracture risk does not impact on falls risk: a post hoc analysis from the SCOOP study.
in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Cox L
(2019)
Ageing here and now: current research and transformative therapies.
in Biogerontology

Cudejko T
(2020)
Minimal shoes improve stability and mobility in persons with a history of falls.
in Scientific reports

Cudejko T
(2020)
Minimal footwear improves stability and physical function in middle-aged and older people compared to conventional shoes.
in Clinical biomechanics (Bristol, Avon)

Cummings S
(2019)
Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates A Meta-analysis
in JAMA Internal Medicine

Cummings SR
(2018)
A History of Pivotal Advances in Clinical Research into Bone and Mineral Diseases.
in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Description | 'Small non-coding RNAs to stratify osteoarthritis in the horse |
Amount | £133,000 (GBP) |
Organisation | Horse Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | ARUK (Bou-Gharios) |
Amount | £413,430 (GBP) |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | ARUK (Bou-Gharios) |
Amount | £251,000 (GBP) |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Aintree Arthritis Trust (Moots, Wright, Edwards) |
Amount | £33,000 (GBP) |
Organisation | Aintree Arthritis Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Aquaporins: A hole in our understanding of hydrogen peroxide regulation |
Amount | £385,108 (GBP) |
Funding ID | BB/T002115/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 08/2019 |
End | 08/2022 |
Description | Association of Physicians (Hannan) |
Amount | £19,850 (GBP) |
Organisation | Association of Physicians of Great Britain and Ireland |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | BBSRC CRISPR-interference Screening Centre (Eeden, Renshaw, Wilkinson) |
Amount | £428,223 (GBP) |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | BBSRC In Vivo Skills award (Pekovic-Vaughan et al) |
Amount | £12,300 (GBP) |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | BBSRC Summer studentship (Peffers) |
Amount | £2,500 (GBP) |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | BRC MIlkMAN (Granic, Stevenson, Aspray, Sayer) |
Amount | £91,041 (GBP) |
Organisation | British Retail Consortium |
Sector | Private |
Country | United Kingdom |
Start |
Description | Biomarkers to predict response to biologic therapy for the stratification of patients to appropriate therapy in rheumatoid arthritis |
Amount | £6,153 (GBP) |
Organisation | Illix Ltd |
Sector | Private |
Country | United Kingdom |
Start |
Description | Biomarkers to predict response to biologic therapy for the stratification of patients to appropriate therapy in rheumatoid arthritis |
Amount | £24,612 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | CRUK Pioneer Award (Zglinicki) |
Amount | £200,000 (GBP) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Circadian rhythms and the control of NRF2-based antioxidant signalling as a therapeutic target in dermal tissue repair and pathological wound healing |
Amount | £448,442 (GBP) |
Funding ID | MR/P003311/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 01/2017 |
End | 01/2020 |
Description | Dowager Countees Eleanor Peel Trust (Henstock) |
Amount | £13,500 (GBP) |
Organisation | The Dowager Countess Eleanor Peel Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Dunhill Medical Trust (Clegg, Screen, Thorpe) |
Amount | £250,000 (GBP) |
Organisation | The Dunhill Medical Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Dunhill Medical Trust (Whysall) |
Amount | £197,222 (GBP) |
Organisation | The Dunhill Medical Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | EU Funding Innovative Medicines Initiative |
Amount | € 12,000,000 (EUR) |
Organisation | European Commission |
Department | Innovative Medicines Initiative (IMI) |
Sector | Public |
Country | Belgium |
Start |
Description | EU Marie Curie (Bernut, Renshaw) |
Amount | £161,000 (GBP) |
Organisation | Marie Curie |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Evaluation of senolytic interventions in skin ageing |
Amount | £361,353 (GBP) |
Funding ID | BB/S006710/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 02/2019 |
End | 01/2022 |
Description | Exploiting microvesicle small non-coding RNA and protein cargo in osteoarthritis for early diagnosis and treatment |
Amount | £272,093 (GBP) |
Organisation | Horserace Betting Levy Board |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Exploiting microvesicle small non-coding RNA and protein cargo in osteoarthritis for early diagnosis and treatment' |
Amount | £272,000 (GBP) |
Organisation | Horserace Betting Levy Board |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Extracellular vesicles as a treatment for osteoarthritis |
Amount | £177,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Frontier Engineering: Progression Grant in Modelling complex and partially identified engineering problems. Application to the musculoskeletal system. |
Amount | £757,886 (GBP) |
Funding ID | EP/S032940/1 |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 08/2019 |
End | 08/2021 |
Description | Health Education England NE (Birrell) |
Amount | £49,500 (GBP) |
Organisation | Health Education England |
Sector | Public |
Country | United Kingdom |
Start |
Description | Healthspan screening in C. Elegans |
Amount | £30,000 (GBP) |
Organisation | European Commission |
Department | European Regional Development Fund (ERDF) |
Sector | Public |
Country | Belgium |
Start |
Description | Hedgehog signalling in ligamentocytes: the role of mechanical loading |
Amount | £10,000 (GBP) |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | Hydrogel-encapsulation for preservation of mitochondria |
Amount | £20,000 (GBP) |
Organisation | European Commission |
Department | European Regional Development Fund (ERDF) |
Sector | Public |
Country | Belgium |
Start |
Description | INSPIRE |
Amount | £10,000 (GBP) |
Organisation | Academy of Medical Sciences (AMS) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Identification of cytokines that drive progression of fibrosis in Dupuytren's disease: therapeutic opportunities with biologics |
Amount | £177,383 (GBP) |
Funding ID | 21809 |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2018 |
End | 07/2020 |
Description | Illix Ltd (Wright, Moots, Edwards) |
Amount | £55,994 (GBP) |
Organisation | Illix Ltd |
Sector | Private |
Country | United Kingdom |
Start |
Description | Innovate UK (Hill) |
Amount | £350,000 (GBP) |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start |
Description | JGW Patterson Foundation (Sorial/Loughlin/Deehan) |
Amount | £52,000 (GBP) |
Organisation | The JGW Patterson Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | KTP Senolytic drug development and Validation |
Amount | £180,643 (GBP) |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start |
Description | KTP award (Miwa/Zglinicki) |
Amount | £181,000 (GBP) |
Organisation | Knowledge Transfer Partnerships |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | MICROAGE: Microgravity as a model for accelerated skeletal muscle ageing |
Amount | £1,165,606 (GBP) |
Funding ID | ST/S003061/1 |
Organisation | UK Space Agency |
Sector | Public |
Country | United Kingdom |
Start | 11/2018 |
End | 10/2021 |
Description | MRC (Renshaw et al) |
Amount | £686,584 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | MRC Project grant (Renshaw) |
Amount | £691,917 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | MRC iCASE Studentships (Renshaw et al) |
Amount | £289,023 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | MRC/ARUK CMAR Studentship (Peffers, Jones) |
Amount | £120,000 (GBP) |
Organisation | Versus Arthritis |
Department | Arthritis Research UK Centre for Musculoskeletal Ageing Research |
Sector | Academic/University |
Country | United Kingdom |
Start |
Description | Metabolic reprogramming of human neutrophils during inflammation |
Amount | £143,064 (GBP) |
Funding ID | 22193 |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 10/2019 |
End | 09/2023 |
Description | MiRNA regulation of Chondrocyte function |
Amount | £130,000 (GBP) |
Organisation | Horse Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Molecular genetic and epigenetic analysis of the chromosome 4p16.3 osteoarthritis risk locus |
Amount | £48,722 (GBP) |
Organisation | The JGW Patterson Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Multi-modal high resolution preclinical PET+SPECT+CT scanner |
Amount | £939,518 (GBP) |
Funding ID | 208389/Z/17/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2017 |
End | 01/2022 |
Description | NC3R grant (Shanley) |
Amount | £389,043 (GBP) |
Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | NIHR HTA (Meher, Hannan) |
Amount | £2,100,000 (GBP) |
Organisation | National Institute for Health Research |
Department | Health Technology Assessment Programme (HTA) |
Sector | Public |
Country | United Kingdom |
Start |
Description | NIHR Newc BRC Project Grant (Birrell) |
Amount | £60,824 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | Newcastle Hospital Trust (Young, Loughlin) |
Amount | £44,000 (GBP) |
Organisation | Newcastle upon Tyne Hospitals NHS Foundation Trust |
Sector | Academic/University |
Country | United Kingdom |
Start |
Description | Newcastle University Group Consultation Virtual Hub: Managing & Preventing Severe Disability Across the UK. |
Amount | £250,000 (GBP) |
Organisation | Sir Jules Thorn Charitable Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Nittobo Evaluation of assay (Eastell) |
Amount | £70,000 (GBP) |
Organisation | Nittobo |
Sector | Private |
Country | Japan |
Start |
Description | Overcoming the barriers to maximize the commercial potential for vitamin D enriched eggs |
Amount | £161,000 (GBP) |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start |
Description | PROvision of braces for Patients with knee OsteoArthritis (PROP OA): a randomised controlled trial |
Amount | £1,622,564 (GBP) |
Funding ID | HTA/16/160/03 |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 09/2018 |
End | 11/2022 |
Description | Precision pathobiology for disease models. |
Amount | € 998,627 (EUR) |
Organisation | European Commission H2020 |
Sector | Public |
Country | Belgium |
Start |
Description | Preventing falls in older people by an innovative connected shoe: development & biomechanics study |
Amount | £575,432 (GBP) |
Funding ID | 104142 |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 02/2020 |
Description | Preventing falls in older people by an innovative connected shoe: development & biomechanics study |
Amount | £74,567,600 (GBP) |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start |
Description | Rapid integrated tendon repair system |
Amount | £98,866 (GBP) |
Funding ID | 22032 |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2019 |
End | 08/2020 |
Description | Royal College Surgeons Edinburgh (Sorial/Loughlin) |
Amount | £60,000 (GBP) |
Organisation | The Royal College of Surgeons of Edinburgh |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Sarcoma UK (Peffers, Balaskas) |
Amount | £20,750 (GBP) |
Organisation | Sarcoma UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | UK Space Agency MICROAGE (Jackson, McArdle, Henstock, Hoettges) |
Amount | £1,291,511 (GBP) |
Organisation | UK Space Agency |
Sector | Public |
Country | United Kingdom |
Start | 11/2018 |
End | 11/2021 |
Description | Understanding the mechanisms and therapeutic potential of targeting biological clocks in Systemic Sclerosis |
Amount | £20,598 (GBP) |
Funding ID | M709 |
Organisation | Rosetrees Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2017 |
End | 04/2021 |
Description | Uni of Georgia pump-priming award (Henstock) |
Amount | £1,000 (GBP) |
Organisation | University of Georgia |
Sector | Academic/University |
Country | United States |
Start |
Description | University of Liverpool (Pefers) |
Amount | £6,300 (GBP) |
Organisation | University of Liverpool |
Sector | Academic/University |
Country | United Kingdom |
Start |
Description | Using Capture C analysis and CRISPR-Cas9 mediated genomic editing to identify the target genes of OA-associated chondrogenic enhancers |
Amount | £62,179 (GBP) |
Organisation | The JGW Patterson Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Utility of PINP to monitor osteoporosis treatment in clinical practice by non-specialist practitioners, the POSE study (PINP and Osteoporosis in Sheffield Evaluation) |
Amount | £93,824 (GBP) |
Organisation | F. Hoffmann-La Roche AG |
Department | Roche Diagnostics |
Sector | Private |
Country | Global |
Start |
Description | Wellcome Trust Summer Scholarship (Henstock) |
Amount | £2,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Title | Fibrotic tissue and healthy ligament |
Description | Human tissue samples derived from surgery as well as cell cultures, tissue extracts and RNA/cDNA derived thereof. |
Type Of Material | Biological samples |
Year Produced | 2018 |
Provided To Others? | No |
Impact | Contributed to CIMA PhD completion and ongoing MRC and Versus Arthritis funded projects. |
Title | Model of age-related bone loss |
Description | Computational model to investigate age-related bone loss |
Type Of Material | Model of mechanisms or symptoms - in vitro |
Year Produced | 2018 |
Provided To Others? | Yes |
Impact | This featured as "Model of the month" in Nov 2018 in Biomodels database |
Title | characterisation of epigenomic changes during chondrogenesis |
Description | Computational model to investigate age-related changes in signalling pathways in OA |
Type Of Material | Model of mechanisms or symptoms - in vitro |
Year Produced | 2019 |
Provided To Others? | Yes |
Impact | TBC |
Title | Characterisation of epigenomic changes during chondrogenesis |
Description | ChIP-seq data from MSC chondrogenesis |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | No |
Impact | Publication submitted |
Title | FRAX 2 dataset |
Description | Tool to develop an updated calculation engine for the FRAX tool |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
Impact | In process |
Title | Proteomic analysis of neutrophil extracellular traps (healthy control, rheumatoid arthritis, systemic lupus erythematosus)_C4PR_LIV |
Description | NET proteomics dataset |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
Impact | TBC |
Title | Spatio-Temporal Atlas of Bone Mineral Density Ageing |
Description | technique utilises an alternating minimisation technique to map the observed bone density measurements into a latent standardised space |
Type Of Material | Data analysis technique |
Year Produced | 2018 |
Provided To Others? | Yes |
Impact | Publication |
Description | IOFIFCC Working group |
Organisation | International Osteoporosis Foundation |
Country | Switzerland |
Sector | Charity/Non Profit |
PI Contribution | Bone turnover markers, collab to produce guidelines on the use of markers |
Collaborator Contribution | As above |
Impact | As above |
Start Year | 2018 |
Title | HPpQCT heel assessment |
Description | Protocol for scanning and analysing heel scans |
Type | Diagnostic Tool - Imaging |
Current Stage Of Development | Early clinical assessment |
Year Development Stage Completed | 2018 |
Development Status | On hold |
Impact | Two publications |
Title | Happy Egg with added vitamin D |
Description | A vitamin D enriched egg product which was developed as a result of an Innovate funded project in 2015 Led to an additional Innovate UK funded project to explore the wider commercial potential for vitamin D enriched eggs |
Type | Preventative Intervention - Nutrition and Chemoprevention |
Current Stage Of Development | Wide-scale adoption |
Year Development Stage Completed | 2018 |
Development Status | Closed |
Impact | See above |
Title | Novel anti-inflammatory compounds |
Description | Compounds originally developed in van 't Hof lab, now licensed to Modern Biosciences and Johnson & Johnson. advised on clinical trials |
Type | Therapeutic Intervention - Drug |
Current Stage Of Development | Late clinical evaluation |
Year Development Stage Completed | 2019 |
Development Status | Under active development/distribution |
Impact | TBC |
Description | Better Together: The Evidence Behind the Headlines A Group Consultation Public Engagement Event on Care and Research |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | An opportunity to ask health related questions, experience how a group consultation works and hear talks from experts in muskuloskeletal research. 25 attending; estimate 500 online Highly interactive session with questions from every attendeee. Excellent feedback from speakers and patients Enthusiasm for similar event at national CIMA meeting |
Year(s) Of Engagement Activity | 2019 |
Description | Dupuytren's PPI panel |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Patients heard about, provided feedback on and discussed current research, and were given tours of the laboratories. Contacts made with new surgical team via patient society, resulting in additional site being added to the study. Patients were keen to return to the next panel meeting. Researchers asked to contribute to webinar for patients. |
Year(s) Of Engagement Activity | 2019 |
Description | Group Consultation National Spread |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Media (as a channel to the public) |
Results and Impact | National publicity associated with RCGP meeting 5/10/18: Front page news: The Sun, Daily Telegraph, Daily Mail, BBC national news BBC1, Radio 4, online |
Year(s) Of Engagement Activity | 2018 |
Description | International Paget's Disease Awereness Day |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | pariticipation through RLBUHT website and social media |
Year(s) Of Engagement Activity | 2019 |
Description | Intro to foot function and ageing for fashion students |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Undergraduate students |
Results and Impact | Liverpool university, fashion students |
Year(s) Of Engagement Activity | 2019 |
Description | Lab visits for 6th form students |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | Lots of questions regarding research, how one does it, and its role in science teaching and in society at large Students enthused to apply to undergraduate university courses |
Year(s) Of Engagement Activity | 2019 |
Description | MRC Festival of Science engagement event, Newcastle |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | 100 people attended and many asked questions on the role of nutrition, especially vitamin D in bone health |
Year(s) Of Engagement Activity | 2018 |
Description | Monthly Group Consultations |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Share evidence underpinning best practice & latest research developments, 13-23 patients per clinic (1000 per year) Better understanding of core management strategy and latest evidence, translating into better care and empowerment High remission rates and evidence of enhanced self- care |
Year(s) Of Engagement Activity | 2018,2019 |
Description | Musculoskeletal biology patient involvement group |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | 6 people with arthritis attended PPI meetings, academics presented project ideas, project results etc and these were discussed as a group Excellent feedback from patient group and requests for more activities |
Year(s) Of Engagement Activity | 2018,2019 |
Description | PPI seminar hosted Bethan Jones UWE and her patient partner, who discussed patient participation in research |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Other audiences |
Results and Impact | 2 patients have expressed a desire to partner PhD students in the institute |
Year(s) Of Engagement Activity | 2019 |
Description | Public engagement at stand at Windsor Horse Show |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | 250 attened the stand and engeged on our equine foot balance activity engage with public interested in equine lameness and foot balance |
Year(s) Of Engagement Activity | 2019 |
Description | Public engagement stand at Liverpool Horse Show |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | 500 people attende the stand over 3 days which had a number of undergard vet students presenting vet related issues including musculoskeletal engage with potential vet students, made conatct with an undergrad who is now my Masters student, invited to give a talk at Chester University on my work |
Year(s) Of Engagement Activity | 2018 |
Description | Session on lessons for healthy ageing from ageing research |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Panel was Tom Kirkwood, Joao Passos, John Mathers and Malcolom Jackson |
Year(s) Of Engagement Activity | 2019 |
Description | Sky TV news item on UKSA award |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | Interview with research team members and filming of laboratory activies |
Year(s) Of Engagement Activity | 2018 |
Description | What really moves you? Public lectures on the wonders of your musculoskeletal system - public talk |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | Oral presentation to approx 60-70 general public attendees ranging in age from primary school to retired adults, followed by questions and answers |
Year(s) Of Engagement Activity | 2016 |
Description | World Arthritis Day Blog |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | TBC |
Year(s) Of Engagement Activity | 2018 |